ONC.TO - Oncolytics Biotech Inc.
| Previous Close | 2.9300 |
| Open | 2.8500 |
| Bid | 2.3600 x 0 |
| Ask | 2.3800 x 0 |
| Day's Range | 2.3600 - 2.8500 |
| 52 Week Range | 1.0600 - 3.1000 |
| Volume | |
| Avg. Volume | 57,621 |
| Market Cap | 151.259M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3300 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.13 |
CNW GroupOncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer, which will be featured in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The webinar will take place on Monday, June 5, 2023 at 8:00 a.m. ET.
- Baystreet
Stocks in play: Oncolytics Biotech Inc
Announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast ...
CNW GroupOncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer. The results are published in an abstract accepted for an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2 – 6, 2023 in Chicago, Illinois and online. The abstract is available on the ASCO Annual Meeting website.
CNW GroupOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
- Baystreet
Stocks in play: Oncolytics Biotech
Today announced recent operational highlights and financial results for the first quarter ended March ...
CNW GroupOncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.
CNW GroupOncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from June 2 – 6, 2023 in Chicago, Illinois and online.
CNW GroupOncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023. Additional details on the panel presentation can be found below.
- CNW Group
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.
- CNW Group
Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is pleased to announce its notice of the annual general meeting of shareholders and management information circular (the "Circular") are now available on the Company's website at: www.oncolyticsbiotech.com as well as under Oncolytics' profile on SEDAR (www.sedar.com). The Company is in the process of mailing the Circular and related materials for the annual general meeting to Oncolytics' shareholders.
- CNW Group
Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be found below.
Simply Wall St.Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Baystreet
Pancreatic Cancer on the Ropes with New Scientific Advancements Including Tests, Worms and Viruses
Despite public battles against pancreatic cancer from celebrities such as Eric Idle and Patrick Swayze, ...
- CNW Group
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the fourth quarter and full year ended December 31, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted.
- CNW Group
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022.
ZacksIs DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
CNW GroupOncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González C
ZacksWhat Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?
Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksOncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
ZacksOncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ZacksIs Olink Holding (OLK) Outperforming Other Medical Stocks This Year?
Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
- CNW Group
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González Convention Center in San Antonio, Texas from December 6 – 10, 2022.
ZacksOncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Baystreet
Oncolytics at Fresh 52-Week High on Drug Results
Oncolytics Biotech Inc. (T.ONC) hit a new 52-week high of $2.50 Thursday. Oncolytics announced updated ...
- CNW Group
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 3